Bio:

Philip Tagari is currently Chief Scientific Officer of insitro, a leading Machine Learning – Drug Discovery company. His team of multidisciplinary scientists and engineers are redefining disease biology and implementing novel approaches to dramatically speed the delivery of meaningful therapeutics to patients with grievous disease. Prior to insitro, Philip spent a decade as Vice President of Research (Therapeutic Discovery) at Amgen Inc. During that time, his global teams advanced over 30 innovative molecules into clinical development and commercialization including Lumukras® (first-in-class KRASG12C inhibitor); Tarlatamab (DLL3 BiTE®); AMG133 (anti-obesity bispecific) and Efavaleukin alfa (AMG 592) a novel IL-2 mutein Fc fusion. He is a Director of CQDM (Consortium Quebecois sur la Decouverte du Medicament; Quebec Consortium for Drug Discovery) and SAB member for BenchSci (biology machine learning) and NutcrackeRx (mRNA therapeutics).

Prior to joining Amgen in 1998, Philip was a Research Fellow at Merck Frosst (Canada) Inc, where he contributed to the discovery of Singulair® and Vioxx®. Philip is a graduate of Gonville & Caius College, Cambridge University (UK), and performed neurobiology research using pioneering quantitative image analysis at McGill and Oxford Universities.